4 results
Efficacy and safety.
Primary: To evaluate the efficacy of FF/UMEC/VI to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Secondary: Long term safety and other efficacy parameters.
To demonstrate the superiority of the combination Nebivolol plus HCTZ versus Irbesartan plus HCTZ in terms of SBP reduction after 12 weeks of treatment in elderly patients with isolated systolic hypertension.
Primary:To compare the effect of UMEC/VI (62.5/25 mcg once daily) with UMEC (62.5 mcg once daily) on lung functionSecondary:To compare UMEC/VI, UMEC with salmeterol (50 mcg twice daily) on patient reported outcomes and on other COPD efficacy…